AzTrials
AzTrials

Radical MastectomyPhase 1/2NCT02065947

Three-level Injection Paravertebral Block vs General Anesthesia in Mastectomy

A Phase 1/2 study testing paravertebral block, fentanyl, propofol, atracurium and lidocaine , adrenaline, ketamine bolus, midazolam in people with Radical Mastectomy, run by Ramathibodi Hospital at 1 site in Thailand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to investigate if paravertebral block for breast surgery may improve postoperative analgesia and shorten length of hospital stay. Within a prospective clinical trial sixty women (ASA I - III) undergoing unilateral mastectomy surgery with axillary dissection are enrolled. Read more about this study

Who is it for?
Ages 18 to 90 years, women onlyHealthy volunteers can take part
Conditions the study is for
Radical Mastectomy
What is being tested?
paravertebral block, fentanyl, propofol, atracurium and lidocaine , adrenaline, ketamine bolus, midazolam
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteThailand
Study dates
Oct 2013to Mar 2014
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Samples are collected after patients' written informed consent in accordance with the Declaration of Helsinki and institutional research board approval. Sixty women (ASA I - III) undergoing unilateral mastectomy surgery with axillary dissection (radical lymph node removal or sentinel node biopsy) are enrolled. Exclusion criteria are general infection and local infection at the site of planned puncture, anatomic deformities of the thoracic spine, coagulation disorders, allergy against local anesthetics or contrast agents, such as Iopamiro 300, pregnancy or breast-feeding and BMI ≥ 30 kg/m2.

Who cannot join

  • Patients who did not meet the inclusion criteria.

Trial locations and contacts

1 site in 1 country.

Thailand1 site
  • Faculty of Medicine Ramathibodi Hospital

    Bangkok, 10400

Other trials in Thailand

About this study

Official title: Three-level Injection Paravertebral Block Using Paravertebral Catheter Compared to General Anesthesia in Mastectomy Surgery

The purpose of the study is to investigate if paravertebral block for breast surgery may improve postoperative analgesia and shorten length of hospital stay. Within a prospective clinical trial sixty women (ASA I - III) undergoing unilateral mastectomy surgery with axillary dissection are enrolled. Exclusion criteria are general infection and local infection at the site of planned puncture, anatomic deformities of the thoracic spine, coagulation disorders, allergy against local anesthetics or contrast agents, pregnancy or breast-feeding and BMI ≥ 30 kg/m2.

Patients are randomly assigned to two groups, 30 patients each, by using block of four method. Group I patients receive paravertebral block at spine level Th 4 via catheter; Group II patients will have general anesthesia without nitrous oxide.

Read more

Paravertebral block (PVB) will be entirely performed by one person (1st author) with the patient in prone position. In randomly selected patients the catheter localization will be detected by fluoroscopy after injection of 0.5 ml contrast agent. The catheter positioned at about 8 cm from skin level, a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000 will be injected sequentially 10 ml each while withdrawing the catheter 2 cm after the first and again 2 cm after the second injection. Then the catheter will be removed. Low dose intraoperative sedation is provided with IV midazolam 2-3 mg, ketamine 0.5 mg/kg bolus and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1 - 1.5 mcg/mL to allow spontaneous breathing. In case surgical approach is not tolerated, the regional block is graded insufficient, and it is switched to general anesthesia.

At postoperative care unit (PACU) the pain score using visual rating scale (VRS) from 0 to 10 (worst imaginable pain) is assessed at rest and on movement of the shoulder every 15 minutes until 60 minutes. Analgesia is provided by IV morphine 0.04 mg/kg boluses with a 15-min dosing interval to maintain VRS - score < 3. Time to first analgesic demand and 24-hr analgesics consumption is recorded as well as postoperative nausea and vomiting (PONV). Complications are recorded including those related to the paravertebral block, such as Horner's syndrome, epidural spreading, hypotension that is not related to another. Patients will be checked 6, 12, and 24hr postoperatively for adverse effects, pain scores, and satisfaction scores.

Read the detailed description

Multiple studies have shown that breast surgery is associated with significant postoperative pain, nausea, vomiting, and development of chronic pain. General anaesthesia is associated with a 50% incidence of nausea and vomiting among breast cancer surgery patients. The proposed benefits of regional anesthesia including paravertebral block compared to general anaesthesia are decreasing stress response, improving postoperative pain control and postoperative pulmonary function, decreasing cancer recurrence, and reducing thromboembolic events. However, the debate about these benefits is still controversial.

Paravertebral block for breast surgery, either alone or additional to general anaesthesia is favored by many investigators, due to better postoperative analgesia and shorter hospital stay. In an elder investigation thermographic imaging was used to apply paravertebral block. After a single injection of 15 ml 0.5% bupivacaine at spine level Th9-Th10 there was a mean distribution of somatic block of five and of sympathetic block of eight dermatomes without any hemodynamic side effects. No bilateral spread was found. The authors contradicted the suggestions paravertebral block being ineffective and sometimes hazardous. However, their patients were chronic pain patients with a number of six only.

Single-injection paravertebral block may not be sufficient to cover the relevant dermatomes C6 - Th6 for radical mastectomy with axillary dissection, when applied as the sole anesthetic technique. Some study groups performed paravertebral block with several injections. Four injections resulted in sufficient anaesthesia in 97% of these patients, whereas one injection was effective in only 11%. Though there is limited published evidence yet, a single injection for paravertebral block may be insufficient for extensive breast surgery, such as mastectomy including axillary evisceration. However, considering the potential risks of deep paravertebral puncture a limitation of punctures would be preferable. Inserting a paravertebral catheter far enough and in proper position offers the opportunity to apply the anesthetic agent at different sites, by moving the catheter backwards after each injection.

The purpose of our study is to find out if injections via paravertebral catheter at three different levels are advantageous and efficient compared to general anesthesia in patients having mastectomy with axillary dissection.

In addition, instead of 4 cm catheter insertion inside the paravertebral space (PVS) as the recommended, we used ultrasound-guided PVB (transverse view, out of plane technique), to facilitate further insertion of the catheter (8 cm) in the PVS. A contrast agent will be used in randomly selected patients to prove the exact site of the inserted catheter and to exclude/detect obstructions such as kinking.

Methods: This is a prospective clinical trial. Patients have to agree documented by written informed consent. Sixty women, ASA I - III undergoing unilateral mastectomy surgery with axillary dissection, including radical lymph node removal or sentinel node biopsy are enrolled.

Patients are randomly assigned to two groups, 30 patients each, by using block of four method. Group I patients receive paravertebral block at spine level Th 4 via catheter with injections at three different levels; Group II patients will have general anesthesia.

Anesthetic preparation: After arrival at the OR standard monitoring is applied including ECG, noninvasive blood pressure and pulse oxymetry. Midazolam 0.05 mg per kilogram bodyweight is given intravenously to all patients to achieve mild sedation.

Paravertebral block (Group I). Paravertebral block will be entirely performed by one person (first author) with the patient in prone position. The superior aspect of the Th4 spinous process is marked. After skin disinfection an 18-gauge Tuohy needle including attached saline filled syringe is inserted perpendicular to the skin at the Th3-Th4 interspace, using the area 2.5 cm lateral to T4 spinous process as Landmark. Under ultrasound guidance, the needle is advanced by out of plane technique, angled anteriorly until contact with the transverse process, and then redirected either caudal or cephalad and parallel to the spine advanced further until loss of resistance. After placement of the needle an end-hole 20 gauge catheter is inserted and advanced 8 cm beyond needlepoint into the paravertebral space. The catheter insertion is scored as 'easy', 'difficult' or 'impossible'. In randomly selected patients the catheter localization will be detected by fluoroscopy after injection of 0.5 ml contrast agent. The catheter positioned, a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000 will be slowly injected sequentially 10 ml each while withdrawing the catheter 2 cm after the first and again 2 cm after the second injection. Then the catheter will be removed. Patients are returned to the supine position and remain for at least 30 minutes in the preoperative area. Sensory blockade is assessed by using pin-prick method.

When analgesia is adequate patients are moved into the operating room. Intraoperative sedation is provided with low dose IV midazolam, ketamine bolus and continuous propofol using target-controlled infusion system to allow spontaneous breathing. In case skin incision or further surgical approach is not tolerated, the regional block is graded insufficient, and it is switched to general anesthesia.

General Anaesthesia (Group II): Anesthesia is induced intravenously with propofol and fentanyl. Atracurium is used to facilitate tracheal intubation. Anesthesia is maintained with sevoflurane and 50% oxygen in air. Additional Fentanyl will be administered on discretion of the anesthesiologist.

Data collection: Patients' biometric data, details of the clinical course, such as amount of anesthetics used, operation time, surgical difficulties, hemodynamic instability (if any) and similar are recorded. At postoperative care unit (PACU) the pain score using visual rating scale from 0 (no pain) to 10 (worst imaginable pain) is assessed at rest and on movement of the shoulder every 15 minutes until 60 minutes. Analgesia is provided by IV morphine boluses with a 15-min dosing interval to maintain VRS - score < 3. Time to first analgesic demand and 24-hr analgesics consumption is recorded. Postoperative nausea and vomiting is assessed using a 3-point scale; Ondansetron is administered to treat it. Any complications are recorded including those related to paravertebral block, such as Horner's syndrome, epidural spreading, hypotension that is not related to another reason, pneumothorax and adverse effect of local anesthetics. Patients will be checked 6, 12, and 24hr postoperatively for adverse effects, pain scores, and satisfaction scores. During hospital stay, the patients receive one tablet of Ultracet (tramadol plus acetaminophen) and Celebrex 200 mg two times a day for pain relief and oral lorazepam before bedtime. Residents or nurses on postoperative care station and surgical ward both are blinded to the treatment groups.

Sample size estimation: According to the data from a previous study paravertebral block compared to general anesthesia can reduce postoperative analgesia requirement (opioids + non-steroidal analgesics) up to 80%. Taking a 5% significance level as basis 30 patients per group is adequate.

Statistical analyses: Parametric data are expressed as mean and analyzed using Student's T test. The non-parametric data are expressed as median (range) and analyzed using Mann-Whitney U Test. Repeated analysis of variance is used to compare VAS between groups. The association between the techniques and incidence of complications are evaluated by chi-square or Fisher's exact test as appropriate. Statistical analyses will be performed using SPSS v20.0 for Windows (SPSS Inc., Chicago, USA). All tests are two-sided and a p-value of < 0.05 is accepted as statistically significant.

Being tested
paravertebral block, fentanyl, propofol, atracurium, lidocaine , adrenaline, ketamine bolus, midazolam, catheter with 3-level-injection, sevoflurane and 50% oxygen in air
Keywords
paravertebral block, mastectomy, efficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • paravertebral blockProcedure or surgery

    Also called 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and TCI propofol at Ce of 1-1.5 mcg/ml

    catheter with 3-level-injection

  • fentanyl, propofol, atracuriumDrug

    endotracheal intubation

  • lidocaine , adrenaline, ketamine bolus, midazolamDrug

    a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL

  • catheter with 3-level-injectionDevice

  • sevoflurane and 50% oxygen in airDrug

Study groups in NCT02065947
Study groupRoleWhat they receive
general anesthesiaActive comparatorfentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
Receives: Drug: fentanyl, propofol, atracurium; Drug: sevoflurane and 50% oxygen in air
paravertebral blockExperimentala mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
Receives: Procedure: paravertebral block; Drug: lidocaine , adrenaline, ketamine bolus, midazolam; Device: catheter with 3-level-injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. postoperative analgesia requirement (opioids + nonsteroidal antiinflammatory drug)

    Measured: 6 months (October 2013 - March 2014)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2014 (estimated)
  2. Study startOct 2013
  3. Primary completionMar 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02065947
Sponsor's protocol ID
MURA 09-56-23
Other IDs
3-LEVEL-PVB
Status last verified
Mar 2014
First submitted
28 Jan 2014
Last updated
10 Mar 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Sundarathiti P, von Bormann B, Suvikapakornkul R, Lertsithichai P, Arnuntasupakul V. Paravertebral Catheter for Three-Level Injection in Radical Mastectomy: A Randomised Controlled Study. PLoS One. 2015 Jun 9;10(6):e0129539. doi: 10.1371/journal.pone.0129539. eCollection 2015.

    PubMed 26056838

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing paravertebral block, fentanyl, propofol, atracurium and lidocaine , adrenaline, ketamine bolus, midazolam in people with Radical Mastectomy, run by Ramathibodi Hospital at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

postoperative analgesia requirement (opioids + nonsteroidal antiinflammatory drug) (time frame: 6 months (October 2013 - March 2014)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02065947, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in